Relmada Therapeutics, Inc. beat EPS estimates 0% of the time across 1 reported quarters (0 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.19 | — | — | Miss |
| Q12026 FY2026 | $-0.18 | $-0.22 | -22.2% | Miss |
Back to RLMD overview · RLMD holders · RLMD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.